Analysts expect Catabasis Pharmaceuticals Inc (NASDAQ:CATB) to announce earnings of ($0.23) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Catabasis Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.23). Catabasis Pharmaceuticals reported earnings per share of ($0.41) in the same quarter last year, which suggests a positive year over year growth rate of 43.9%. The company is expected to report its next earnings results on Thursday, May 10th.
On average, analysts expect that Catabasis Pharmaceuticals will report full-year earnings of ($0.92) per share for the current year, with EPS estimates ranging from ($0.92) to ($0.91). For the next year, analysts forecast that the firm will post earnings of ($1.48) per share, with EPS estimates ranging from ($1.64) to ($1.32). Zacks’ EPS averages are a mean average based on a survey of analysts that follow Catabasis Pharmaceuticals.
Catabasis Pharmaceuticals (NASDAQ:CATB) last posted its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.07. The company had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.25 million.
Institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its stake in Catabasis Pharmaceuticals by 146.1% in the 4th quarter. Geode Capital Management LLC now owns 76,612 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 45,476 shares in the last quarter. Deutsche Bank AG purchased a new position in Catabasis Pharmaceuticals in the 4th quarter valued at approximately $335,000. Finally, Renaissance Technologies LLC grew its stake in Catabasis Pharmaceuticals by 167.2% in the 4th quarter. Renaissance Technologies LLC now owns 468,700 shares of the biotechnology company’s stock valued at $698,000 after buying an additional 293,300 shares in the last quarter. Institutional investors and hedge funds own 27.94% of the company’s stock.
Catabasis Pharmaceuticals stock traded down $0.01 during mid-day trading on Monday, reaching $1.76. The company’s stock had a trading volume of 133,599 shares, compared to its average volume of 930,355. Catabasis Pharmaceuticals has a 12-month low of $1.09 and a 12-month high of $3.78. The firm has a market capitalization of $51.39, a price-to-earnings ratio of -1.40 and a beta of 0.68.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3344370/analysts-expect-catabasis-pharmaceuticals-inc-catb-will-post-earnings-of-0-23-per-share.html.
About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.